Inventor

SHULDINER ALAN

US15 patents

⚠️ This page may combine multiple inventors who share the name “SHULDINER ALAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

REGENERON PHARMA

12 patents

US10787647B2Sep 29, 2020

17β-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof

REGENERON PHARMA3 citations71

US11485958B2Nov 1, 2022

HSD17B13 variants and uses thereof

REGENERON PHARMA1 citations70

US11713461B2Aug 1, 2023

Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors

REGENERON PHARMA2 citations69

US12359201B2Jul 15, 2025

17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof

REGENERON PHARMA0 citations61

US12509687B2Dec 30, 2025

Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors

REGENERON PHARMA0 citations59

US11331332B2May 17, 2022

Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors

REGENERON PHARMA0 citations58

US12480103B2Nov 25, 2025

B4GALT1 variants and uses thereof

REGENERON PHARMA0 citations53

US11504390B2Nov 22, 2022

Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors

REGENERON PHARMA0 citations47

US10738284B2Aug 11, 2020

B4GALT1 cDNA variants and compositions comprising the same

REGENERON PHARMA0 citations42

UNIV MARYLAND

3 patents

US7312197B2Dec 25, 2007

Method of modifying glucose activity using polypeptides selectively expressed in fat tissue

UNIV MARYLAND16 citations87

US7550435B2Jun 23, 2009

Method of modifying glucose activity using polypeptides selectively expressed in fat tissue

UNIV MARYLAND2 citations57

US10463716B2Nov 5, 2019

Methods for treating cardiovascular dysfunction and improving fluid homeostasis with Elabela peptide hormone

UNIV MARYLAND0 citations48